UA61955C2 - Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy - Google Patents

Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy Download PDF

Info

Publication number: UA61955C2
Authority: UA; Ukraine
Prior art keywords: mavrs157; disorders; rgo; rko; salt
Prior art date: 1997-05-23

Application number

UA99127002A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-23

Filing date

1998-05-20

Publication date

2003-12-15

1998-05-20 Application filed filed Critical

2003-12-15 Publication of UA61955C2 publication Critical patent/UA61955C2/uk

Links

150000003839 salts Chemical class 0.000 title claims abstract description 94
230000000694 effects Effects 0.000 title claims description 105
238000004519 manufacturing process Methods 0.000 title description 3
238000002560 therapeutic procedure Methods 0.000 title description 3
150000001768 cations Chemical class 0.000 claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
150000001875 compounds Chemical class 0.000 claims abstract description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 85
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 85
238000000034 method Methods 0.000 claims description 61
108090000765 processed proteins & peptides Proteins 0.000 claims description 54
208000035475 disorder Diseases 0.000 claims description 53
239000000243 solution Substances 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 41
230000003902 lesion Effects 0.000 claims description 37
201000010099 disease Diseases 0.000 claims description 32
230000035882 stress Effects 0.000 claims description 30
230000006378 damage Effects 0.000 claims description 28
238000011161 development Methods 0.000 claims description 25
230000009471 action Effects 0.000 claims description 24
230000015572 biosynthetic process Effects 0.000 claims description 23
210000002784 stomach Anatomy 0.000 claims description 21
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 17
210000001035 gastrointestinal tract Anatomy 0.000 claims description 16
210000000056 organ Anatomy 0.000 claims description 14
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 13
206010020772 Hypertension Diseases 0.000 claims description 13
229940025084 amphetamine Drugs 0.000 claims description 13
230000001120 cytoprotective effect Effects 0.000 claims description 12
206010033645 Pancreatitis Diseases 0.000 claims description 11
208000018737 Parkinson disease Diseases 0.000 claims description 11
208000025865 Ulcer Diseases 0.000 claims description 10
208000027418 Wounds and injury Diseases 0.000 claims description 10
-1 n MH Chemical class 0.000 claims description 10
230000003238 somatosensory effect Effects 0.000 claims description 10
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 10
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
230000007170 pathology Effects 0.000 claims description 9
231100000397 ulcer Toxicity 0.000 claims description 9
BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 claims description 8
206010010904 Convulsion Diseases 0.000 claims description 8
125000000539 amino acid group Chemical group 0.000 claims description 8
239000002585 base Substances 0.000 claims description 8
206010012601 diabetes mellitus Diseases 0.000 claims description 8
210000001198 duodenum Anatomy 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 8
208000001953 Hypotension Diseases 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 7
206010033647 Pancreatitis acute Diseases 0.000 claims description 7
201000003229 acute pancreatitis Diseases 0.000 claims description 7
206010003246 arthritis Diseases 0.000 claims description 7
230000006870 function Effects 0.000 claims description 7
208000014674 injury Diseases 0.000 claims description 7
210000004698 lymphocyte Anatomy 0.000 claims description 7
210000001519 tissue Anatomy 0.000 claims description 7
206010061218 Inflammation Diseases 0.000 claims description 6
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
239000007983 Tris buffer Substances 0.000 claims description 6
230000004054 inflammatory process Effects 0.000 claims description 6
230000008816 organ damage Effects 0.000 claims description 6
210000004556 brain Anatomy 0.000 claims description 5
230000036543 hypotension Effects 0.000 claims description 5
230000000302 ischemic effect Effects 0.000 claims description 5
210000000265 leukocyte Anatomy 0.000 claims description 5
239000003176 neuroleptic agent Substances 0.000 claims description 5
230000000701 neuroleptic effect Effects 0.000 claims description 5
208000020431 spinal cord injury Diseases 0.000 claims description 5
208000030507 AIDS Diseases 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
206010002383 Angina Pectoris Diseases 0.000 claims description 4
206010003694 Atrophy Diseases 0.000 claims description 4
206010013654 Drug abuse Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
206010040070 Septic Shock Diseases 0.000 claims description 4
208000006011 Stroke Diseases 0.000 claims description 4
206010052428 Wound Diseases 0.000 claims description 4
208000038016 acute inflammation Diseases 0.000 claims description 4
230000006022 acute inflammation Effects 0.000 claims description 4
230000002776 aggregation Effects 0.000 claims description 4
238000004220 aggregation Methods 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 4
230000037444 atrophy Effects 0.000 claims description 4
208000037976 chronic inflammation Diseases 0.000 claims description 4
230000005796 circulatory shock Effects 0.000 claims description 4
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 4
201000001881 impotence Diseases 0.000 claims description 4
210000005036 nerve Anatomy 0.000 claims description 4
210000000578 peripheral nerve Anatomy 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
230000003612 virological effect Effects 0.000 claims description 4
208000020401 Depressive disease Diseases 0.000 claims description 3
201000004624 Dermatitis Diseases 0.000 claims description 3
206010012438 Dermatitis atopic Diseases 0.000 claims description 3
206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
206010041303 Solar dermatitis Diseases 0.000 claims description 3
208000027520 Somatoform disease Diseases 0.000 claims description 3
206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 3
208000024780 Urticaria Diseases 0.000 claims description 3
230000002159 abnormal effect Effects 0.000 claims description 3
230000002378 acidificating effect Effects 0.000 claims description 3
150000001340 alkali metals Chemical class 0.000 claims description 3
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
150000001342 alkaline earth metals Chemical class 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
208000010668 atopic eczema Diseases 0.000 claims description 3
230000002903 catalepsic effect Effects 0.000 claims description 3
230000000768 catecholaminergic effect Effects 0.000 claims description 3
230000006020 chronic inflammation Effects 0.000 claims description 3
208000010877 cognitive disease Diseases 0.000 claims description 3
230000004064 dysfunction Effects 0.000 claims description 3
230000008694 endothelial dysfunction Effects 0.000 claims description 3
230000001771 impaired effect Effects 0.000 claims description 3
208000017169 kidney disease Diseases 0.000 claims description 3
208000019423 liver disease Diseases 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
230000007935 neutral effect Effects 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
208000027753 pain disease Diseases 0.000 claims description 3
210000002345 respiratory system Anatomy 0.000 claims description 3
201000000980 schizophrenia Diseases 0.000 claims description 3
201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 3
208000011117 substance-related disease Diseases 0.000 claims description 3
230000005951 type IV hypersensitivity Effects 0.000 claims description 3
208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 3
208000007848 Alcoholism Diseases 0.000 claims description 2
206010053567 Coagulopathies Diseases 0.000 claims description 2
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
230000024932 T cell mediated immunity Effects 0.000 claims description 2
206010001584 alcohol abuse Diseases 0.000 claims description 2
208000025746 alcohol use disease Diseases 0.000 claims description 2
150000001450 anions Chemical class 0.000 claims description 2
208000015294 blood coagulation disease Diseases 0.000 claims description 2
230000009852 coagulant defect Effects 0.000 claims description 2
208000019622 heart disease Diseases 0.000 claims description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
210000001672 ovary Anatomy 0.000 claims description 2
230000008855 peristalsis Effects 0.000 claims description 2
206010039083 rhinitis Diseases 0.000 claims description 2
150000003512 tertiary amines Chemical class 0.000 claims description 2
210000001215 vagina Anatomy 0.000 claims description 2
150000003141 primary amines Chemical class 0.000 claims 2
208000018478 Foetal disease Diseases 0.000 claims 1
206010021519 Impaired healing Diseases 0.000 claims 1
206010034277 Pemphigoid Diseases 0.000 claims 1
206010061363 Skeletal injury Diseases 0.000 claims 1
208000000594 bullous pemphigoid Diseases 0.000 claims 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 claims 1
230000035874 hyperreactivity Effects 0.000 claims 1
150000001413 amino acids Chemical class 0.000 abstract description 9
208000031295 Animal disease Diseases 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
150000007529 inorganic bases Chemical class 0.000 abstract 1
150000007530 organic bases Chemical class 0.000 abstract 1
241000700159 Rattus Species 0.000 description 72
241001465754 Metazoa Species 0.000 description 58
230000037396 body weight Effects 0.000 description 56
239000000463 material Substances 0.000 description 38
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 34
238000002474 experimental method Methods 0.000 description 34
241000282412 Homo Species 0.000 description 26
241000699670 Mus sp. Species 0.000 description 26
210000000988 bone and bone Anatomy 0.000 description 26
230000018109 developmental process Effects 0.000 description 24
230000035876 healing Effects 0.000 description 23
102000004196 processed proteins & peptides Human genes 0.000 description 23
239000004475 Arginine Substances 0.000 description 22
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
230000002829 reductive effect Effects 0.000 description 20
238000012360 testing method Methods 0.000 description 20
239000003814 drug Substances 0.000 description 19
230000001681 protective effect Effects 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
230000036772 blood pressure Effects 0.000 description 17
229960002504 capsaicin Drugs 0.000 description 17
235000017663 capsaicin Nutrition 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 17
230000001965 increasing effect Effects 0.000 description 17
HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 16
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 16
229940079593 drug Drugs 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
230000007423 decrease Effects 0.000 description 14
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
238000002329 infrared spectrum Methods 0.000 description 14
230000008092 positive effect Effects 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
238000004458 analytical method Methods 0.000 description 12
208000032843 Hemorrhage Diseases 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
208000009386 Experimental Arthritis Diseases 0.000 description 10
230000000875 corresponding effect Effects 0.000 description 10
UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 10
230000007547 defect Effects 0.000 description 10
229960003638 dopamine Drugs 0.000 description 10
229960003151 mercaptamine Drugs 0.000 description 10
238000009806 oophorectomy Methods 0.000 description 10
230000004044 response Effects 0.000 description 10
238000001356 surgical procedure Methods 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
230000009286 beneficial effect Effects 0.000 description 9
230000002496 gastric effect Effects 0.000 description 9
230000003313 weakening effect Effects 0.000 description 9
239000007864 aqueous solution Substances 0.000 description 8
230000000740 bleeding effect Effects 0.000 description 8
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 8
229960003878 haloperidol Drugs 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
210000003734 kidney Anatomy 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
230000000069 prophylactic effect Effects 0.000 description 8
238000003307 slaughter Methods 0.000 description 8
239000000126 substance Substances 0.000 description 8
206010063560 Excessive granulation tissue Diseases 0.000 description 7
206010028851 Necrosis Diseases 0.000 description 7
241000700605 Viruses Species 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000000654 additive Substances 0.000 description 7
229960004679 doxorubicin Drugs 0.000 description 7
230000003511 endothelial effect Effects 0.000 description 7
210000001126 granulation tissue Anatomy 0.000 description 7
230000001976 improved effect Effects 0.000 description 7
229960000905 indomethacin Drugs 0.000 description 7
238000001819 mass spectrum Methods 0.000 description 7
230000017074 necrotic cell death Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
238000002211 ultraviolet spectrum Methods 0.000 description 7
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
208000009132 Catalepsy Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
208000002193 Pain Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 6
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
206010047853 Waxy flexibility Diseases 0.000 description 6
230000003872 anastomosis Effects 0.000 description 6
238000010171 animal model Methods 0.000 description 6
238000005452 bending Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
229960003529 diazepam Drugs 0.000 description 6
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
230000036407 pain Effects 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 6
229960003147 reserpine Drugs 0.000 description 6
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 6
239000007787 solid Substances 0.000 description 6
206010002091 Anaesthesia Diseases 0.000 description 5
230000037005 anaesthesia Effects 0.000 description 5
206010003119 arrhythmia Diseases 0.000 description 5
210000001185 bone marrow Anatomy 0.000 description 5
210000005013 brain tissue Anatomy 0.000 description 5
239000002775 capsule Substances 0.000 description 5
210000003038 endothelium Anatomy 0.000 description 5
210000001156 gastric mucosa Anatomy 0.000 description 5
230000009931 harmful effect Effects 0.000 description 5
210000002216 heart Anatomy 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
208000028867 ischemia Diseases 0.000 description 5
229960003350 isoniazid Drugs 0.000 description 5
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
208000002815 pulmonary hypertension Diseases 0.000 description 5
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 5
229960004291 sucralfate Drugs 0.000 description 5
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
206010048610 Cardiotoxicity Diseases 0.000 description 4
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
206010020565 Hyperaemia Diseases 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
241000700157 Rattus norvegicus Species 0.000 description 4
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
210000004100 adrenal gland Anatomy 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000006793 arrhythmia Effects 0.000 description 4
210000000013 bile duct Anatomy 0.000 description 4
229960002802 bromocriptine Drugs 0.000 description 4
231100000259 cardiotoxicity Toxicity 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000036461 convulsion Effects 0.000 description 4
230000007850 degeneration Effects 0.000 description 4
229960003914 desipramine Drugs 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
210000004211 gastric acid Anatomy 0.000 description 4
244000144993 groups of animals Species 0.000 description 4
RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 4
238000002513 implantation Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000011068 loading method Methods 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
210000004400 mucous membrane Anatomy 0.000 description 4
230000002265 prevention Effects 0.000 description 4
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 4
229960000620 ranitidine Drugs 0.000 description 4
238000011084 recovery Methods 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
235000019155 vitamin A Nutrition 0.000 description 4
239000011719 vitamin A Substances 0.000 description 4
229940045997 vitamin a Drugs 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010001497 Agitation Diseases 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
229930003347 Atropine Natural products 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
241000208011 Digitalis Species 0.000 description 3
102000015554 Dopamine receptor Human genes 0.000 description 3
108050004812 Dopamine receptor Proteins 0.000 description 3
208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
206010020880 Hypertrophy Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
230000007059 acute toxicity Effects 0.000 description 3
231100000403 acute toxicity Toxicity 0.000 description 3
210000003766 afferent neuron Anatomy 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000003288 anthiarrhythmic effect Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
239000003699 antiulcer agent Substances 0.000 description 3
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
229960000396 atropine Drugs 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 3
229910001626 barium chloride Inorganic materials 0.000 description 3
230000006399 behavior Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
150000003943 catecholamines Chemical class 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
235000013330 chicken meat Nutrition 0.000 description 3
230000007665 chronic toxicity Effects 0.000 description 3
231100000160 chronic toxicity Toxicity 0.000 description 3
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 3
229960001380 cimetidine Drugs 0.000 description 3
230000009194 climbing Effects 0.000 description 3
230000003930 cognitive ability Effects 0.000 description 3
230000003750 conditioning effect Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000009547 development abnormality Effects 0.000 description 3
239000003210 dopamine receptor blocking agent Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000013110 gastrectomy Methods 0.000 description 3
208000013403 hyperactivity Diseases 0.000 description 3
230000009610 hypersensitivity Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
230000035800 maturation Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
238000013425 morphometry Methods 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
238000013059 nephrectomy Methods 0.000 description 3
208000004235 neutropenia Diseases 0.000 description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
229960003712 propranolol Drugs 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000033764 rhythmic process Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000011664 signaling Effects 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000003506 spasmogen Substances 0.000 description 3
230000004006 stereotypic behavior Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
206010001605 Alcohol poisoning Diseases 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010003671 Atrioventricular Block Diseases 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
102400000967 Bradykinin Human genes 0.000 description 2
101800004538 Bradykinin Proteins 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
208000031404 Chromosome Aberrations Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
206010072170 Skin wound Diseases 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
230000003257 anti-anginal effect Effects 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
230000003502 anti-nociceptive effect Effects 0.000 description 2
230000000767 anti-ulcer Effects 0.000 description 2
239000003416 antiarrhythmic agent Substances 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
231100001018 bone marrow damage Toxicity 0.000 description 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
230000007885 bronchoconstriction Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
231100000005 chromosome aberration Toxicity 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000037319 collagen production Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000000254 damaging effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000002183 duodenal effect Effects 0.000 description 2
208000000718 duodenal ulcer Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229960001596 famotidine Drugs 0.000 description 2
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
239000000835 fiber Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
229960002690 fluphenazine Drugs 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000007902 hard capsule Substances 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
210000002767 hepatic artery Anatomy 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000002631 hypothermal effect Effects 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
238000002350 laparotomy Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000012866 low blood pressure Diseases 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
230000004678 mucosal integrity Effects 0.000 description 2
210000003007 myelin sheath Anatomy 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
230000002188 osteogenic effect Effects 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
235000021400 peanut butter Nutrition 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
229960002646 scopolamine Drugs 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
210000001044 sensory neuron Anatomy 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229960004940 sulpiride Drugs 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
206010047302 ventricular tachycardia Diseases 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
UHLRPXXFPYMCAE-UHFFFAOYSA-N 4-isopropylcalix[4]arene Chemical compound C1C(C=2O)=CC(C(C)C)=CC=2CC(C=2O)=CC(C(C)C)=CC=2CC(C=2O)=CC(C(C)C)=CC=2CC2=CC(C(C)C)=CC1=C2O UHLRPXXFPYMCAE-UHFFFAOYSA-N 0.000 description 1
208000012124 AIDS-related disease Diseases 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
206010001541 Akinesia Diseases 0.000 description 1
208000029197 Amphetamine-Related disease Diseases 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
101100381867 Candida albicans MDR1 gene Proteins 0.000 description 1
241001631457 Cannula Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
206010012441 Dermatitis bullous Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018473 Glycosuria Diseases 0.000 description 1
208000031856 Haemosiderosis Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
229910016006 MoSi Inorganic materials 0.000 description 1
102400001103 Neurotensin Human genes 0.000 description 1
101800001814 Neurotensin Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000004531 Renal Artery Obstruction Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038378 Renal artery stenosis Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010038468 Renal hypertrophy Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
201000003099 Renovascular Hypertension Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
206010042008 Stereotypy Diseases 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
208000013200 Stress disease Diseases 0.000 description 1
206010042220 Stress ulcer Diseases 0.000 description 1
241001279009 Strychnos toxifera Species 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
241000779819 Syncarpia glomulifera Species 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000028505 alcohol-related disease Diseases 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
206010053552 allodynia Diseases 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
201000002472 amphetamine abuse Diseases 0.000 description 1
239000003708 ampul Substances 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000003270 anti-cataleptic effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940124345 antianginal agent Drugs 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000002639 bone cement Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
239000012659 cardioprotective agent Substances 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
230000037326 chronic stress Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000003179 convulsant agent Substances 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002897 effect on convulsion Effects 0.000 description 1
230000001516 effect on protein Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000008753 endothelial function Effects 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000012048 forced swim test Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
208000016616 gastric juice peptides Diseases 0.000 description 1
231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
230000002178 gastroprotective effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000006750 hematuria Diseases 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
230000002443 hepatoprotective effect Effects 0.000 description 1
208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000004276 hyalin Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007654 ischemic lesion Effects 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
230000009191 jumping Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000008627 kidney hypertrophy Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
231100000149 liver necrosis Toxicity 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229960002523 mercuric chloride Drugs 0.000 description 1
LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000037891 myocardial injury Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000023561 neuropathy, hereditary sensory and autonomic, type 2A Diseases 0.000 description 1
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229960003057 nialamide Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008447 perception Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000001739 pinus spp. Substances 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000012501 relaxation of skeletal muscle Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
229960005453 strychnine Drugs 0.000 description 1
229940120904 succinylcholine chloride Drugs 0.000 description 1
YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009182 swimming Effects 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
229940036248 turpentine Drugs 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
208000001319 vasomotor rhinitis Diseases 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
230000001018 virulence Effects 0.000 description 1
235000015041 whisky Nutrition 0.000 description 1
208000016153 withdrawal disease Diseases 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Psychology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

UA99127002A 1997-05-23 1998-05-20 Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy UA61955C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP97108384		1997-05-23
PCT/EP1998/002953 WO1998052973A1 (en)	1997-05-23	1998-05-20	New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy

Publications (1)

Publication Number	Publication Date
UA61955C2 true UA61955C2 (en)	2003-12-15

Family

ID=8226822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99127002A UA61955C2 (en)	1997-05-23	1998-05-20	Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy

Country Status (28)

Country	Link
US (1)	US6288028B1 (pl)
EP (1)	EP0983300B1 (pl)
JP (1)	JP3492381B2 (pl)
KR (1)	KR100488038B1 (pl)
CN (1)	CN1166683C (pl)
AR (1)	AR011478A1 (pl)
AT (1)	ATE277948T1 (pl)
AU (1)	AU731317B2 (pl)
BG (1)	BG64023B1 (pl)
BR (1)	BR9809457B1 (pl)
CA (1)	CA2290739C (pl)
CZ (1)	CZ299423B6 (pl)
DE (1)	DE69826653T2 (pl)
DK (1)	DK0983300T3 (pl)
EA (1)	EA002058B1 (pl)
ES (1)	ES2229507T3 (pl)
HU (1)	HU227800B1 (pl)
ID (1)	ID23184A (pl)
IL (2)	IL132884A0 (pl)
NO (1)	NO321126B1 (pl)
NZ (1)	NZ501323A (pl)
PL (1)	PL193790B1 (pl)
PT (1)	PT983300E (pl)
RS (1)	RS49733B (pl)
SK (1)	SK159599A3 (pl)
TR (1)	TR199902866T2 (pl)
UA (1)	UA61955C2 (pl)
WO (1)	WO1998052973A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4912875B2 (ja) *	2004-02-27	2012-04-11	不二製油株式会社	癌転移抑制組成物
US8022216B2 (en) *	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SI24318A (sl) *	2013-03-13	2014-09-30	Diagen D.O.O.	Nove stabilne soli pentadekapeptida, postopek za njihovo pripravo, njihova uporaba za izdelavo farmacevtskih pripravkov in njihova uporaba v terapiji
US10350293B2 (en) *	2016-08-23	2019-07-16	Pharmacotherapia d.o.o.	Compositions and methods for treating symptoms associated with multiple sclerosis
BR112020002804A2 (pt)	2017-08-24	2020-07-28	Novo Nordisk A/S	composição farmacêutica líquida, e, kit
IL294521A (en)	2020-02-18	2022-09-01	Novo Nordisk As	glp-1 compounds and their uses
US11065298B1 (en) *	2020-04-24	2021-07-20	Chanda Zaveri	Compositions and methods for treating or preventing viral infections
US12605427B2 (en) *	2023-05-15	2026-04-21	Red Mountain Med Spa, LLC	Sublingual semaglutide-BPC 157 combination for weight loss

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2591875B2 (ja) *	1990-09-11	1997-03-19	プレドラグシキリク	薬理学的活性物質ｂｐｃ、その製造方法及びこれを治療に使用する方法
EP0572688B1 (en) *	1992-05-30	1997-05-07	Predrag Dr.Sc. Sikiric	Peptides with organo-protective activity, the process for preparing them and their use in therapy
RO115733B1 (ro) *	1992-11-16	2000-05-30	Predrag Sikiric	Peptide cu activitate organo-protectoare

1998
- 1998-05-20 WO PCT/EP1998/002953 patent/WO1998052973A1/en not_active Ceased
- 1998-05-20 ID IDW991444A patent/ID23184A/id unknown
- 1998-05-20 CN CNB988053934A patent/CN1166683C/zh not_active Expired - Fee Related
- 1998-05-20 KR KR10-1999-7010862A patent/KR100488038B1/ko not_active Expired - Fee Related
- 1998-05-20 SK SK1595-99A patent/SK159599A3/sk unknown
- 1998-05-20 PL PL98336897A patent/PL193790B1/pl unknown
- 1998-05-20 AT AT98929345T patent/ATE277948T1/de active
- 1998-05-20 TR TR1999/02866T patent/TR199902866T2/xx unknown
- 1998-05-20 US US09/424,414 patent/US6288028B1/en not_active Expired - Lifetime
- 1998-05-20 HU HU0002329A patent/HU227800B1/hu not_active IP Right Cessation
- 1998-05-20 NZ NZ501323A patent/NZ501323A/en not_active IP Right Cessation
- 1998-05-20 JP JP54994898A patent/JP3492381B2/ja not_active Expired - Fee Related
- 1998-05-20 ES ES98929345T patent/ES2229507T3/es not_active Expired - Lifetime
- 1998-05-20 DK DK98929345T patent/DK0983300T3/da active
- 1998-05-20 PT PT98929345T patent/PT983300E/pt unknown
- 1998-05-20 AU AU79141/98A patent/AU731317B2/en not_active Ceased
- 1998-05-20 CA CA002290739A patent/CA2290739C/en not_active Expired - Fee Related
- 1998-05-20 DE DE69826653T patent/DE69826653T2/de not_active Expired - Lifetime
- 1998-05-20 EA EA199901061A patent/EA002058B1/ru not_active IP Right Cessation
- 1998-05-20 EP EP98929345A patent/EP0983300B1/en not_active Expired - Lifetime
- 1998-05-20 RS YUP-601/99A patent/RS49733B/sr unknown
- 1998-05-20 CZ CZ0414299A patent/CZ299423B6/cs not_active IP Right Cessation
- 1998-05-20 IL IL13288498A patent/IL132884A0/xx active IP Right Grant
- 1998-05-20 UA UA99127002A patent/UA61955C2/uk unknown
- 1998-05-20 BR BRPI9809457-2A patent/BR9809457B1/pt not_active IP Right Cessation
- 1998-05-26 AR ARP980102425A patent/AR011478A1/es active IP Right Grant
1999
- 1999-11-11 IL IL132884A patent/IL132884A/en not_active IP Right Cessation
- 1999-11-19 NO NO19995692A patent/NO321126B1/no not_active IP Right Cessation
- 1999-11-19 BG BG103905A patent/BG64023B1/bg unknown

Also Published As

Publication number	Publication date
CN1257510A (zh)	2000-06-21
ATE277948T1 (de)	2004-10-15
CA2290739C (en)	2007-06-26
KR100488038B1 (ko)	2005-05-09
CN1166683C (zh)	2004-09-15
WO1998052973A1 (en)	1998-11-26
AU731317B2 (en)	2001-03-29
HU227800B1 (en)	2012-03-28
BR9809457A (pt)	2000-06-20
NO995692D0 (no)	1999-11-19
PT983300E (pt)	2005-02-28
HUP0002329A1 (hu)	2000-12-28
TR199902866T2 (xx)	2000-02-21
IL132884A (en)	2007-08-19
NO321126B1 (no)	2006-03-20
HUP0002329A3 (en)	2001-03-28
CZ299423B6 (cs)	2008-07-23
AR011478A1 (es)	2000-08-16
CA2290739A1 (en)	1998-11-26
BG64023B1 (bg)	2003-10-31
US6288028B1 (en)	2001-09-11
NO995692L (no)	2000-01-24
SK159599A3 (en)	2000-11-07
JP2000515558A (ja)	2000-11-21
AU7914198A (en)	1998-12-11
EA199901061A1 (ru)	2000-06-26
EP0983300B1 (en)	2004-09-29
BG103905A (en)	2000-07-31
BR9809457B1 (pt)	2010-11-30
PL336897A1 (en)	2000-07-17
ID23184A (id)	2000-03-23
EP0983300A1 (en)	2000-03-08
DE69826653T2 (de)	2006-03-09
DK0983300T3 (da)	2005-01-31
EA002058B1 (ru)	2001-12-24
CZ9904142A3 (cs)	2002-03-13
KR20010012895A (ko)	2001-02-26
ES2229507T3 (es)	2005-04-16
NZ501323A (en)	2001-04-27
DE69826653D1 (de)	2004-11-04
PL193790B1 (pl)	2007-03-30
YU60199A (sh)	2002-09-19
RS49733B (sr)	2008-04-04
IL132884A0 (en)	2001-03-19
JP3492381B2 (ja)	2004-02-03

Publication	Publication Date	Title
EA028343B1 (ru)	2017-11-30	Лечение дегенеративного заболевания сустава
KR20160070077A (ko)	2016-06-17	안구내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조 방법
JP2017524024A (ja)	2017-08-24	関節病態の治療
BR112020013033A2 (pt)	2020-12-01	composição farmacêutica, uso da composição farmacêutica, e, método para tratamento de uma doença inflamatória.
EP3682016A1 (en)	2020-07-22	Formulations for compound delivery
BR112015022212B1 (pt)	2023-05-02	Sais estáveis de pentadecapeptídeo, seu processo de preparo, seu uso e formulação farmacêutica
KR20220079621A (ko)	2022-06-13	척수 손상의 치료 및/또는 재수초화를 위한 펩타이드의 전신 투여
US6288028B1 (en)	2001-09-11	BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy
PT1562577E (pt)	2012-01-12	Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas pela talidomida
CN116077512A (zh)	2023-05-09	曼那斯汀减轻化疗药物顺铂导致的多器官损伤的应用
RU2252779C1 (ru)	2005-05-27	Способ профилактики и лечения язв желудочно-кишечного тракта
PT1443943E (pt)	2010-12-03	Processo para a reacção de alcalóides e uso dos produtos de reacção na preparação de medicamentos
RU2564907C1 (ru)	2015-10-10	Способ лечения больных красным плоским лишаем
RU2717674C1 (ru)	2020-03-25	Лекарственное средство, усиливающее оксигенацию тканей при диабетической стопе, и способ его применения
ES3015257T3 (en)	2025-04-30	Levetiracetam, brivaracetam or selectracetam for use in treating sepsis induced acute brain dysfunction
JP7235658B2 (ja)	2023-03-08	疼痛治療のためのａｎｇ（１－７）誘導体オリゴペプチド
CN101355947B (zh)	2013-06-05	用于治疗的噻唑并嘧啶类
CN122055146A (zh)	2026-05-15	Pde5抑制剂组合于促进神经突生长的新颖用途
JP2008542369A (ja)	2008-11-27	Ａｖｒ１１８を用いて苦痛緩和医療を提供する方法
HRP20010006A2 (en)	2003-06-30	New peptide salts with organo-protective activity, the process for their preparation and their use in therapy
JPS6344728B2 (pl)	1988-09-06
JP2004168729A (ja)	2004-06-17	神経ペプチドの産生・放出抑制剤